Socioeconomic disparities in vestibular schwannoma diagnosis and management: A systematic review.

Neurosurg RevSep 22, 2026 (epub)
Clinical ResearchNeurosurgeryOpen access

Anne R Lally, Rachel L Welch, Anthony Terraciano et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated socioeconomic disparities in the diagnosis and management of vestibular schwannoma (VS) among adult patients. Analyzing 40 studies, it found that race and insurance status were the most consistently associated factors influencing treatment and outcomes. The review included a total of 358,843 patients, highlighting significant inequities in care.

Key findings

  • Race and insurance status were the most frequently reported socioeconomic variables affecting VS management.
  • Disparities in care were linked to differences in treatment selection, outcomes, and complications.
  • Few studies assessed functional status, hearing outcomes, or quality of life in VS patients.

Why it matters

Understanding socioeconomic disparities in vestibular schwannoma care is crucial for improving patient outcomes and ensuring equitable access to treatment. Addressing these disparities can lead to better management strategies and health equity in neurosurgical care.

Source

PubMed · PMID 42771071Free full text on PubMed Central

Published in Neurosurg Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurosurgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.